Life AI Net
홈
아카이브
계산기
디렉토리
뉴스레터
Hot
로그인
한국어
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
홈
아카이브
계산기
디렉토리
뉴스레터
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
로그인
홈
아카이브
계산기
디렉토리
More
실시간
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
아카이브
검색
검색
최신
오래된 순
지우기
@BioWorld
전체
1057
출처
BioWorld
검색어
--
BioWorld
2026년 3월 23일
In the clinic for March 23, 2026
BioWorld
2026년 3월 23일
Other news to note for March 23, 2026
BioWorld
2026년 3월 23일
Regulatory actions for March 23, 2026
BioWorld
2026년 3월 23일
Biggest gainers and losers for March 16-20, 2026
BioWorld
2026년 3월 23일
Daiichi Sankyo patents SF-1 degradation inducers
BioWorld
2026년 3월 23일
BTK inhibitors disclosed in Ewha Womans University patent
BioWorld
2026년 3월 23일
Abbisko synthesizes new GTPase KRAS mutant inhibitors
BioWorld
2026년 3월 20일
Biopharma money raised: Jan. 1-March 20, 2026
BioWorld
2026년 3월 20일
Money raised by biopharma
BioWorld
2026년 3월 20일
Other news to note for March 20, 2026
BioWorld
2026년 3월 20일
Regulatory actions for March 20, 2026
BioWorld
2026년 3월 20일
After judge’s injunction, will ACIP disband?
BioWorld
2026년 3월 20일
Synnovation’s PI3Kα inhibitor portfolio draws Novartis in $3B deal
BioWorld
2026년 3월 20일
FDA, NIH mark milestones toward reducing animal testing
BioWorld
2026년 3월 20일
Treeline Biosciences reports TEAD degraders
BioWorld
2026년 3월 20일
Muscarinic M4 receptor PAMs disclosed in Suven Life Sciences patent
BioWorld
2026년 3월 20일
Omass Therapeutics identifies melanocortin MC2 receptor antagonists
BioWorld
2026년 3월 20일
ADPD 2026: Three inflection points to target Alzheimer’s disease
이전
12 / 59
다음